Literature DB >> 11710917

Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid.

S Verraes1, W Hornebeck, M Polette, L Borradori, P Bernard.   

Abstract

Bullous pemphigoid is a blistering disorder associated with autoantibodies directed against two components of hemidesmosomes, BP180 and BP230. Autoantibodies to the extracellular collagenous domain of BP180 are thought to play a key role in the pathogenesis of the disease. In a murine model of bullous pemphigoid, neutrophil elastase and 92 kDa gelatinase (matrix metalloproteinase 9) have been implicated in subepidermal blister formation via proteolytic degradation of BP180. In this study we sought to elucidate the contribution of these two enzymes to subepidermal blister formation by assessing the expression, localization, and activity of the two proteases in lesional skin, serum samples, and blister fluids obtained from 17 patients with bullous pemphigoid. The results indicate that (i) neutrophil elastase is found in skin biopsy specimens from bullous pemphigoid lesions and is recovered as active enzyme in blister fluids, and (ii) although proform of matrix metalloproteinase 9 is present in lesional skin, it is present only as proenzyme in blister fluids, which also contain high levels of tissue inhibitor of metalloproteinase-1. Next, the capacity of matrix metalloproteinase 9 and neutrophil elastase to degrade a recombinant protein corresponding to the extracellular collagenous domain of the BP180 was studied. Our data illustrate that (i) recombinant matrix metalloproteinase 9, neutrophil elastase, and blister fluid from bullous pemphigoid patients are all able to hydrolyze recombinant BP180; (ii) the pattern of recombinant BP180 proteolysis with blister fluid was similar to that obtained with neutrophil elastase; and (iii) recombinant BP180 degradation by blister fluid could be inhibited by chloromethylketone, a specific elastase inhibitor, but not by batimastat, a wide spectrum matrix metalloproteinase inhibitor. Our results confirm the importance of neutrophil elastase but not matrix metalloproteinase 9 in the direct cleavage of BP180 autoantigen and subepidermal blister formation in human bullous pemphigoid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710917     DOI: 10.1046/j.0022-202x.2001.01521.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  30 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Radio-induced bullous pemphigoid.

Authors:  Joaquín J Cabrera-Rodríguez; Julia L Muñoz-García; Juan Quirós Rivero; Francisca Ropero Carmona; Yésica Ríos Kavadoy
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

3.  Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid.

Authors:  C Günther; G Wozel; M Meurer; C Pfeiffer
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

4.  Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.

Authors:  Zhi Liu; Ning Li; Luis A Diaz; Michael Shipley; Robert M Senior; Zena Werb
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  Neutrophil elastase cleaves the murine hemidesmosomal protein BP180/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid.

Authors:  Lan Lin; Tomoko Betsuyaku; Lisa Heimbach; Ning Li; David Rubenstein; Steven D Shapiro; Lijia An; George J Giudice; Luis A Diaz; Robert M Senior; Zhi Liu
Journal:  Matrix Biol       Date:  2011-09-25       Impact factor: 11.583

Review 6.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.

Authors:  Mohsen Afarideh; Robert Borucki; Victoria P Werth
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

7.  Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.

Authors:  Zhi Liu; Wen Sui; Minglang Zhao; Zhuowei Li; Ning Li; Randy Thresher; George J Giudice; Janet A Fairley; Cassian Sitaru; Detlef Zillikens; Gang Ning; M Peter Marinkovich; Luis A Diaz
Journal:  J Autoimmun       Date:  2008-10-14       Impact factor: 7.094

Review 8.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

9.  Autoantibody Profile of a Cohort of 54 Italian Patients with Linear IgA Bullous Dermatosis: LAD-1 Denoted as a Major Auto-antigen of the Lamina Lucida Subtype.

Authors:  Emanuele Cozzani; Giovanni Di Zenzo; Giulia Gasparini; Adele Salemme; Arianna Fay Agnoletti; Camilla Vassallo; Marzia Caproni; Emiliano Antiga; Angelo V Marzano; Riccardo Cavalli; Corrado Ocella; Clara de Simone; Aurora Parodi
Journal:  Acta Derm Venereol       Date:  2020-02-29       Impact factor: 3.875

Review 10.  Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid.

Authors:  Lisa Leighty; Ning Li; Luis A Diaz; Zhi Liu
Journal:  Arch Dermatol Res       Date:  2007-09-19       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.